This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Arrowhead Research Corporation (ARWR)
Alvos Acquisition Conference Call
April 11, 2012 4:30 PM ET
Brooks Rahmer – IR
Christopher Anzalone – CEO
Ted Tenthoff – Piper Jaffray
Good day and welcome to the Arrowhead Alvos Therapeutics Acquisition conference call and webcast. All participants will be in a listen-only mode.
Please also note that today’s event is being recorded. I would now like to turn the conference call over to Christopher Anzalone. Mr. Anzalone, please go ahead.
Thanks operator. Good afternoon everyone and thank you for joining us on the call today. With us – Brooks Rahmer?
Hi, guys. Think I will say a few words. Thanks everybody for joining the call today. On the call with us are President and CEO Dr. Christopher Anzalone, COO Dr. Bruce Given, and CFO Ken Myszkowski.
Management will provide a brief overview of the acquisition and will then open the call up to your questions.
Before we begin, I would like to remind you that comments made during today's call may contain certain forward-looking statements within the meaning of Section 27(A) of the Securities Act of 1933 and Section 21(E) of the Securities Exchange Act of 1934.
All statements other than statements of historical fact, including without limitation those with respect to Arrowhead's goals, plans, and strategies are forward-looking statements. Without limiting the generality of the foregoing, words such as may, will, expect, believe, anticipate, intend, could, estimate, or continue, or the negative or other variations thereof, or comparable terminology, are intended to identify forward-looking statements.